These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31759879)

  • 1. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
    Papp KV; Buckley R; Mormino E; Maruff P; Villemagne VL; Masters CL; Johnson KA; Rentz DM; Sperling RA; Amariglio RE;
    Alzheimers Dement; 2020 Mar; 16(3):552-560. PubMed ID: 31759879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 3. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
    Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
    Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.
    Buckley RF; Mormino EC; Amariglio RE; Properzi MJ; Rabin JS; Lim YY; Papp KV; Jacobs HIL; Burnham S; Hanseeuw BJ; Doré V; Dobson A; Masters CL; Waller M; Rowe CC; Maruff P; Donohue MC; Rentz DM; Kirn D; Hedden T; Chhatwal J; Schultz AP; Johnson KA; Villemagne VL; Sperling RA; ; ;
    Alzheimers Dement; 2018 Sep; 14(9):1193-1203. PubMed ID: 29803541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
    Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
    J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
    Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
    Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.
    Pudumjee SB; Lundt ES; Albertson SM; Machulda MM; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM; Stricker NH
    J Alzheimers Dis; 2021; 83(2):861-877. PubMed ID: 34366338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease.
    Buckley RF; Maruff P; Ames D; Bourgeat P; Martins RN; Masters CL; Rainey-Smith S; Lautenschlager N; Rowe CC; Savage G; Villemagne VL; Ellis KA;
    Alzheimers Dement; 2016 Jul; 12(7):796-804. PubMed ID: 26852195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.
    Vos SJ; Xiong C; Visser PJ; Jasielec MS; Hassenstab J; Grant EA; Cairns NJ; Morris JC; Holtzman DM; Fagan AM
    Lancet Neurol; 2013 Oct; 12(10):957-65. PubMed ID: 24012374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.